Ausztrália - angol - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - doxorubicin hydrochloride, quantity: 2 mg/ml - injection, concentrated - excipient ingredients: ammonium sulfate; histidine; water for injections; sodium hydroxide; cholesterol; sodium methoxy peg-40-carbonyl-distearoylphosphatidylethanolamine; sucrose; hydrogenated soy phosphatidylcholine; hydrochloric acid - for the treatment of aids-related kaposi's sarcoma (ks) in patients with low cd4 counts (<200 lymphocytes/mm) and extensive mucocutaneous or visceral disease. caelyx may be used for first-line systemic chemotherapy, or as second line chemotherapy in aids-ks patients with disease that has progressed with, or in patients intolerant to, prior combination systemic chemotherapy comprising at least two of the following agents: a vinca alkaloid, bleomycin and doxorubicin (or other anthracycline). indications as at 21 september 2001: for the treatment of: (1) advanced epithelial ovarian cancer in women who have failed a first-line platinum-based chemotherapy regimen. (2) aids-related kaposi's sarcoma (ks) in patients with low cd4 counts (<200 lymphocytes/cubic mm) and extensive mucocutaneous or visceral disease. as first-line systemic chemotherapy, or as second line chemotherapy in aids-ks patients with disease that has progressed with, or in patients intolerant to, prior combination systemic chemotherapy comprising at least two of the following agents: a vinca alkaloid, bleomycin and doxorubicin (or other anthracycline). indications as at 29 february 2008: caelyx, as monotherapy, is indicated for the treatment of metastatic breast cancer. caelyx is also indicated for the treatment of: advanced epithelial ovarian cancer in women who have failed a first-line platinum-based chemotherapy regimen. aids-related kaposi's sarcoma (ks) in patients with low cd4 counts (<200 lymphocytes/mm3) and extensive mucocutaneous or visceral disease. caelyx may be used as first-line systemic chemotherapy, or as second line chemotherapy in aids-ks patients with disease that has progressed with, or in patients intolerant to, prior combination systemic chemotherapy comprising at least two of the following agents: a vinca alkaloid, bleomycin and doxorubicin (or other anthracycline). caelyx is also indicated, in combination with bortezomib, for the treatment of progressive multiple myeloma in patients who have received at least one prior therapy and who have already undergone or who are unsuitable for bone marrow transplant.

Egyesült Államok - angol - NLM (National Library of Medicine)

hf acquisition co llc, dba healthfirst - chromic chloride (unii: kb1pcr9dmw) (chromic cation - unii:x1n4508kf1) - chromium 4 mcg/ml (chromic chloride injection, usp) is indicated for use as a supplement to intravenous solutions given for tpn. administration helps to maintain chromium serum levels and to prevent depletion of endogenous stores and subsequent deficiency symptoms. none known. none known.

Ausztrália - angol - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - chromic chloride hexahydrate, quantity: 5.33 microgram/ml; ferric chloride hexahydrate, quantity: 540 microgram/ml; sodium selenite, quantity: 17.29 microgram/ml; sodium fluoride, quantity: 210 microgram/ml; cupric chloride dihydrate, quantity: 102.3 microgram/ml; potassium iodide, quantity: 16.6 microgram/ml; sodium molybdate dihydrate, quantity: 4.85 microgram/ml; manganese chloride tetrahydrate, quantity: 19.79 microgram/ml; zinc chloride, quantity: 1.05 mg/ml - injection, concentrated - excipient ingredients: water for injections; hydrochloric acid; xylitol - to meet basal to moderately increased requirements of trace elements in parenteral nutrition in adults, when either oral or enteral nutrition is inappropriate

Málta - angol - Medicines Authority

fresenius kabi limited cestrian court, eastgate way, manor park, runcorn, cheshire wa7 1nt, united kingdom - chromic chloride, potassium iodide, copper chloride, ferric chloride, zinc chloride, manganese chloride, sodium fluoride, sodium molybdate, sodium selenite - concentrate for solution for infusion - chromic chloride 5.33 µg potassium iodide 16.6 µg copper chloride 340 µg ferric chloride 544 µg zinc chloride 1.36 mg manganese chloride 99 µg sodium fluoride 210 µg sodium molybdate 4.85 µg sodium selenite 10.5 µg - blood substitutes and perfusion solutions

Ausztrália - angol - Department of Health (Therapeutic Goods Administration)

metagenics (aust) pty ltd - ascorbic acid,betacarotene,borax,biotin,calcium amino acid chelate,calcium citrate tetrahydrate,calcium hydrogen phosphate dihydrate,calcium pantothenate,chromic chloride hexahydrate,colecalciferol,cyanocobalamin,d-alpha-tocopheryl acid succinate,dibasic potassium phosphate,folic acid,heavy magnesium oxide,magnesium amino acid chelate,manganese amino acid chelate,mixed (low-alpha type) tocopherols concentrate,molybdenum trioxide,nicotinamide,phytomenadione,potassium iodide,pyridoxal -

Egyesült Államok - angol - NLM (National Library of Medicine)

stat rx usa llc - cevimeline hydrochloride (unii: p81q6v85np) (cevimeline - unii:k9v0cdq56e) - cevimeline hydrochloride 30 mg - cevimeline is indicated for the treatment of symptoms of dry mouth in patients with sjögren’s syndrome. cevimeline is contraindicated in patients with uncontrolled asthma, known hypersensitivity to cevimeline, and when miosis is undesirable, e.g., in acute iritis and in narrow-angle (angle-closure) glaucoma.

Egyesült Államok - angol - NLM (National Library of Medicine)

american regent, inc. - zinc sulfate heptahydrate (unii: n57ji2k7wp) (zinc cation - unii:13s1s8sf37), cupric sulfate (unii: lrx7aj16dt) (cupric cation - unii:8cbv67279l), manganese sulfate (unii: w00lys4t26) (manganese cation (2+) - unii:h6ep7w5457), chromic chloride (unii: kb1pcr9dmw) (chromic cation - unii:x1n4508kf1) - zinc cation 6.6 mg in 1 ml - multitrace ® - 4 neonatal is indicated for use as a supplement to intravenous solutions given for tpn. administration of multitrace ® - 4 neonatal in tpn solutions helps to maintain plasma levels of zinc, copper, manganese, and chromium and to prevent depletion of endogenous stores of these trace elements and subsequent deficiency symptoms. multitrace ® - 4 neonatal should not be given undiluted by direct injection into a peripheral vein because of the potential of infusion phlebitis.

Egyesült Államok - angol - NLM (National Library of Medicine)

unit dose services - ziprasidone hydrochloride (unii: 216x081oru) (ziprasidone - unii:6uka5vej6x) - ziprasidone 20 mg - ziprasidone hydrochloride capsules are indicated for the treatment of schizophrenia. when deciding among the alternative treatments available for the condition needing treatment, the prescriber should consider the finding of ziprasidone's greater capacity to prolong the qt/qtc interval compared to several other antipsychotic drugs [see warnings and precautions (5.2)]. prolongation of the qtc interval is associated in some other drugs with the ability to cause torsade de pointes-type arrhythmia, a potentially fatal polymorphic ventricular tachycardia, and sudden death. in many cases this would lead to the conclusion that other drugs should be tried first. whether ziprasidone will cause torsade de pointes or increase the rate of sudden death is not yet known [see warnings and precautions (5.2)]. ziprasidone hydrochloride capsules are indicated for the treatment of schizophrenia. the efficacy of oral ziprasidone was established in four short-term (4- and 6-week) controlled trials of adult schizophrenic inpatien

Egyesült Államok - angol - NLM (National Library of Medicine)

pd-rx pharmaceuticals, inc. - paroxetine hydrochloride hemihydrate (unii: x2els050d8) (paroxetine - unii:41vrh5220h) - paroxetine 20 mg - paroxetine tablets are indicated for the treatment of major depressive disorder. the efficacy of paroxetine tablets in the treatment of a major depressive episode was established in 6-week controlled trials of outpatients whose diagnoses corresponded most closely to the dsm-iii category of major depressive disorder (see clinical pharmacology: clinical trials). a major depressive episode implies a prominent and relatively persistent depressed or dysphoric mood that usually interferes with daily functioning (nearly every day for at least 2 weeks); it should include at least 4 of the following 8 symptoms: change in appetite, change in sleep, psychomotor agitation or retardation, loss of interest in usual activities or decrease in sexual drive, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, and a suicide attempt or suicidal ideation. the effects of paroxetine tablets in hospitalized depressed patients have not been adequately studied. the efficacy of paroxetine t

Egyesült Államok - angol - NLM (National Library of Medicine)

mylan institutional inc. - paroxetine hydrochloride hemihydrate (unii: x2els050d8) (paroxetine - unii:41vrh5220h) - paroxetine 20 mg - paroxetine tablets are indicated for the treatment of major depressive disorder. the efficacy of paroxetine tablets in the treatment of a major depressive episode was established in 6-week controlled trials of outpatients whose diagnoses corresponded most closely to the dsm-iii category of major depressive disorder (see clinical pharmacology: clinical trials). a major depressive episode implies a prominent and relatively persistent depressed or dysphoric mood that usually interferes with daily functioning (nearly every day for at least 2 weeks); it should include at least 4 of the following 8 symptoms: change in appetite, change in sleep, psychomotor agitation or retardation, loss of interest in usual activities or decrease in sexual drive, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, and a suicide attempt or suicidal ideation. the effects of paroxetine tablets in hospitalized depressed patients have not been ade